These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 716950)

  • 1. Studies on the correlation between rate of biotransformation and haematological toxicity of cyclophosphamide.
    Mouridsen HT; Witten J; Frederiksen PL; Hulsbaek I
    Acta Pharmacol Toxicol (Copenh); 1978 Oct; 43(4):328-30. PubMed ID: 716950
    [No Abstract]   [Full Text] [Related]  

  • 2. The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.
    Mouridsen HT; Faber O; Skovsted L
    Acta Pharmacol Toxicol (Copenh); 1974 Aug; 35(2):98-106. PubMed ID: 4479366
    [No Abstract]   [Full Text] [Related]  

  • 3. "Refractory" thrombocytopenic purpura treated successfully with cyclophosphamide.
    Laros RK; Penner JA
    JAMA; 1971 Jan; 215(3):445-9. PubMed ID: 5107390
    [No Abstract]   [Full Text] [Related]  

  • 4. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone.
    Bagley CM; Devita VT; Berard CW; Canellos GP
    Ann Intern Med; 1972 Feb; 76(2):227-34. PubMed ID: 5066691
    [No Abstract]   [Full Text] [Related]  

  • 5. Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma.
    Buckner CD; Briggs R; Clift RA; Fefer A; Funk DD; Glucksberg H; Neiman PE; Storb R; Thomas ED
    Cancer Chemother Rep; 1974; 58(5 Pt 1):697-703. PubMed ID: 4426048
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses.
    Bergsagel DE; Robertson GL; Hasselback R
    Can Med Assoc J; 1968 Mar; 98(11):532-8. PubMed ID: 5643297
    [No Abstract]   [Full Text] [Related]  

  • 7. The biotransformation of cyclophosphamide in man: influence of prednisone.
    Faber OK; Mouridsen HT; Skovsted L
    Acta Pharmacol Toxicol (Copenh); 1974 Sep; 35(3):195-200. PubMed ID: 4479295
    [No Abstract]   [Full Text] [Related]  

  • 8. Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms.
    Tran A; Bournerias F; Le Beller C; Mir O; Rey E; Pons G; Delahousse M; Tréluyer JM
    Br J Clin Pharmacol; 2008 Feb; 65(2):279-80. PubMed ID: 17875191
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms.
    Buckner CD; Clift RA; Fefer A; Funk DD; Glucksberg H; Neiman PE; Paulsen A; Storb R; Thomas ED
    Cancer Chemother Rep; 1974; 58(5 Pt 1):709-14. PubMed ID: 4609599
    [No Abstract]   [Full Text] [Related]  

  • 10. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.
    Muggia FM; Perloff M; Chia GA; Reed LJ; Escher GC
    Cancer Chemother Rep; 1974; 58(6):919-26. PubMed ID: 4614899
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962).
    Curtis JE
    Cancer Chemother Rep; 1974; 58(6):883-8. PubMed ID: 4614897
    [No Abstract]   [Full Text] [Related]  

  • 12. EXPERIMENTAL BRAIN PERFUSION.
    HUGOSSON R; NORDSTROEM S; SILANDER T
    Surgery; 1964 Mar; 55():427-35. PubMed ID: 14133101
    [No Abstract]   [Full Text] [Related]  

  • 13. I.v. melphalan in carcinoma of the lung: effect of cyclophosphamide priming on hematopoietic toxicity.
    Spitzer G; Valdivieso M; Farha P; Murphy WK; Dhingra HM; Chiuten D; Umsawasdi T; Holoye P
    Cancer Treat Rep; 1986 Apr; 70(4):449-53. PubMed ID: 3698037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).
    Friberg LE; Brindley CJ; Karlsson MO; Devlin AJ
    Eur J Clin Pharmacol; 2000 Nov; 56(8):567-74. PubMed ID: 11151746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man.
    Faber OK; Mouridsen HT; Skovsted L
    Br J Clin Pharmacol; 1975 Jun; 2(3):281-5. PubMed ID: 791322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity.
    Waselenko JK; Burrows A; Nelson DA; Lucas M; Ekstrand J; Edenfield WJ; Myhand RC
    Ann Hematol; 2003 Sep; 82(9):552-7. PubMed ID: 12910372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent cyclophosphamide treatment of autoimmune thombocytopenia.
    Weinerman B; Maxwell I; Hryniuk W
    Can Med Assoc J; 1974 Nov; 111(10):1100-2. PubMed ID: 4473260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
    Kennedy MJ; Zahurak ML; Donehower RC; Noe D; Grochow LB; Sartorius S; Chen TL; Bowling K; Duerr M; Rowinsky EK
    Clin Cancer Res; 1998 Feb; 4(2):349-56. PubMed ID: 9516922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased half life of cyclophosphamide in patients under continual treatment.
    D'Incalci M; Bolis G; Facchinetti T; Mangioni C; Morasca L; Morazzoni P; Salmona M
    Eur J Cancer (1965); 1979 Jan; 15(1):7-10. PubMed ID: 421718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.